Idorsia Ltd
SIX:IDIA
Idorsia Ltd
Research & Development
Idorsia Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Idorsia Ltd
SIX:IDIA
|
Research & Development
-CHf98.4m
|
CAGR 3-Years
37%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Research & Development
-$112.9m
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Research & Development
-$284.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-37%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Research & Development
-CHf81.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Research & Development
-CHf8.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Research & Development
-CHf1.2m
|
CAGR 3-Years
62%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Idorsia Ltd
Glance View
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
See Also
What is Idorsia Ltd's Research & Development?
Research & Development
-98.4m
CHF
Based on the financial report for Sep 30, 2025, Idorsia Ltd's Research & Development amounts to -98.4m CHF.
What is Idorsia Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
24%
Over the last year, the Research & Development growth was 37%. The average annual Research & Development growth rates for Idorsia Ltd have been 37% over the past three years , 24% over the past five years .
